Over the past two decades, psoriatic arthritis (PsA) therapy has evolved from broad immunosuppression to highly targeted biologic and small-molecule interventions. Agents blocking TNF, IL-17A/F, IL-23, IL-12/23, or JAK signaling have transformed outcomes for many patients. Yet these therapies share a key limitation: they suppress inflammation without restoring immune tolerance. Furthermore, treatment must be continued indefinitely, relapses are common, and a subset of patients progress to difficult-to-treat (D2T) disease despite multiple mechanisms of action (1).

Meanwhile, the field of engineered T-cell therapies, most notably chimeric antigen receptor (CAR) T-cell therapy, has expanded beyond oncology. Early successes of CD19-directed CAR-T cells in refractory lupus and other autoimmune diseases have renewed interest in cellular therapies that can recalibrate autoreactive networks rather than merely dampen downstream cytokine pathways (2). A related and rapidly emerging technology, CAR-engineered regulatory T cells (CAR-Tregs), offers a fundamentally different approach: localized, antigen-targeted induction of immune tolerance (3).

Recent advances in spatial immunology, single-cell transcriptomics, and immunopeptidomics have substantially refined our understanding of tissue-imprinted immune responses in chronic inflammatory diseases. In parallel, rapid progress in regulatory T-cell engineering, including optimized CAR designs and safety switches, has expanded the feasibility of tolerance-inducing cellular therapies beyond transplantation and oncology. Given the tissue-specific immunopathology of PsA, an important question arises as to whether PsA could become a future candidate for CAR-Treg–based interventions.

Advances in single-cell transcriptomics and T-cell receptor (TCR) sequencing have demonstrated that PsA shows prominent clonal expansions of CD8⁺ T cells in synovial tissue and the enthesis (4–6). These cells display Tc17 and Tc1 effector phenotypes and produce IL-17A, IL-22, GM-CSF, and IFN-γ, reflecting activation by cytokines, stromal cues and biomechanical stress (4–6). The enthesis, once considered a purely structural organ, is now understood as an immune microenvironment enriched with IL-23R⁺ resident T cells responsive to microdamage and mechanical loading (7).

TRM cells illustrate a fundamental limit of cytokine-blocking strategies as biologics suppress effector pathways but do not remodel the tissue-imprinted immune architecture sustaining chronicity (1, 9). This insight provides a rationale for therapies capable of modulating microenvironments directly—such as CAR-Tregs—which could, in principle, suppress TRM-dominated inflammation at its origin.

PsA exhibits several characteristics that make it theoretically well-aligned with CAR-Treg strategies. A spatially defined, tissue-specific disease: the enthesis acts as a micro-organ where immune cells, stromal signals, and mechanical forces converge (7). Localized modulation is therefore attractive. TRM-dominated microenvironments: persistent TRM populations maintain inflammatory potential even when systemic inflammation is controlled—ideal for a therapy that acts at the tissue level (8). Shared antigens between skin and musculoskeletal tissues: some autoantigen candidates overlap between psoriasis lesions and PsA joints, improving the feasibility of tissue-targeted CAR constructs (4). Unmet needs in difficult-to-treat PsA: patients failing ≥2 biologic classes represent a small but significant unmet need group and may justify advanced cellular therapies (11). Potential antigenic targets: although speculative, conceivable targets for CAR-Tregs include extracellular matrix neoepitopes in inflamed entheses, stress-induced or mechanically generated peptides, shared motifs detected via immunopeptidomics, and stromal or fibroblast-associated molecules enriched in PsA (12).

Psoriatic arthritis exemplifies the paradox of modern immunology where, despite the availability of highly effective cytokine-targeted therapies, truly lasting remission remains difficult to achieve for many patients (1). Current treatments excel at extinguishing inflammatory activity but fall short of reshaping the underlying immunological architecture that sustains chronicity. The enthesis and synovium are not passive tissues but immunologically active microenvironments in which T cells, stromal elements, and mechanical stimuli converge. These sites serve as reservoirs of inflammation capable of reactivation even when systemic cytokine levels are well controlled, illustrating the limitations of a pharmacologic model rooted primarily in cytokine blockade (1).

A growing body of single-cell and spatial immunology research highlights the centrality of clonal CD8⁺ T-cell expansions and tissue-resident memory T cells (TRM) in PsA pathogenesis (4–7). TRM cells create lasting, tissue-specific immune memory that remains well after clinical remission. Their ability to respond rapidly to local cues—mechanical stress, IL-23 bursts, or stromal activation—likely contributes to the well-known phenomenon of site-specific disease recurrence (7, 8). Importantly, current biologics modulate TRM effector function but do not erase TRM populations or reverse their residency programs. This biological reality underscores why even deep responses to IL-23 or IL-17 inhibition may not equate to immune resolution at the tissue level (1, 9).

These insights explain, at least in part, why PsA displays a plateau of therapeutic response. Biologics are highly effective at interrupting inflammatory cascades but do not comprehensively address the local immune ecosystems that propagate and sustain the disease (7). The disparity between systemic suppression and tissue-level persistence underscores a therapeutic limitation: current interventions are insufficient to achieve tissue-specific immune tolerance.

Within this framework, emerging cellular immunotherapies—specifically CAR-Tregs—offer a conceptual shift. Unlike cytotoxic CAR-T cells, CAR-Tregs are engineered not to deplete pathogenic cells but to actively restore immune regulation within diseased tissues (3, 10). Their mechanism of action is multifaceted: precise homing to antigens or microenvironmental structures, bystander suppression of local effector T cells, modulation of antigen-presenting cells, remodeling of fibroblast–immune interactions, and secretion of regulatory cytokines such as IL-10 and TGF-β (3, 10). These effects are inherently tissue-targeted and therefore map closely onto the immunobiology of PsA.

Preclinical studies have shown that CAR-Tregs can promote antigen-specific tolerance in transplantation, autoimmune encephalomyelitis, colitis, and cardiac inflammation (10). Their safety profile appears more favorable than traditional CAR-T platforms, with a low risk of cytokine release syndrome and a reduced likelihood of off-target tissue damage (3, 10). Importantly, CAR-Tregs offer the potential to reshape the immune landscape of a particular tissue, not just to suppress its inflammatory outputs (3). This makes them uniquely suited for conditions driven by durable, tissue-embedded immune programs such as PsA.

PsA also presents several features that could position it as a future candidate for CAR-Treg development. It is a spatially defined disease, most prominently affecting the enthesis, where immune and mechanical cues intersect (7). Disease-driving T-cell populations, including TRM and Tc17/Tc1 subsets, are enriched and clonally expanded locally (4). Some antigenic pathways appear to be shared between skin and musculoskeletal tissues, offering a conceptual foothold for the design of tissue-homing CAR constructs. Finally, a subset of patients with difficult-to-treat PsA—those failing multiple biologic mechanisms or displaying aggressive structural progression—represent a clinically meaningful unmet need in whom advanced therapies could be justified (11).

However, many challenges remain. The absence of a universal PsA antigen complicates CAR targeting; antigen discovery efforts must advance substantially before rational CAR construction is feasible. FOXP3 stability, phenotypic drift, and the long-term persistence of engineered Tregs are active areas of investigation (13–15). Technical barriers in Treg expansion, manufacturing, and cost remain substantial, and ethical considerations will be central when applying genetically engineered therapies to a chronic, non-lethal disease. Regulatory pathways under the ATMP framework will also shape the translational trajectory.

Despite these limitations, scientific convergence is compelling. Advances in tissue-peptidomics, TCR clonotyping, and spatial immunology are rapidly expanding our understanding of antigenic landscapes within PsA tissues (4–7). Parallel progress in Treg engineering—such as optimized CAR designs, safety switches, and “universal donor” platforms—may soon reduce some of the technical obstacles (13–15). Together, these emerging capabilities suggest that PsA could become a model condition for exploring targeted immune-tolerance strategies.

In summary, CAR-Treg therapy is not imminent for PsA, and its feasibility remains speculative. Yet its underlying logic aligns uniquely with the immunobiology of the disease. If future research continues to elucidate tissue-specific antigenic drivers and refine Treg engineering technologies, CAR-Tregs may represent a new frontier in PsA management: one that moves beyond cytokine blockade toward the restoration of local immune homeostasis (Table 1). Whether PsA ultimately becomes a proving ground for this approach will depend on the next decade of discovery at the intersection of immunology, rheumatology, and cellular biotechnology.